The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...

In a recent study published in Neurology - Neuroimmunology Neuroinflammation, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on the progression of clinical disability in ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

How do we assess the needs of people with severe multiple disabilities? Unable to communicate verbally and physically, this population has nearly no possibility of expressing itself. Thanks to ...

Using eye-tracking -- a technique for recording and analyzing eye movements -- a team has shown that individuals with multiple disabilities can improve their social and emotional skills. Although ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

Please provide your email address to receive an email when new articles are posted on . Medical student burnout is an important quality assessment metric in medicine. Students with multiple ...

DEDHAM - A Dedham woman is trying to take the stigma out of disability aids. Noelle Connolly has been living with multiple sclerosis symptoms since she was 17 and was officially diagnosed at 23. "I ...

A new study conducted by researchers from the Corrine Goldsmith Dickinson Center for Multiple Sclerosis at Icahn School of Medicine at Mount Sinai in collaboration with Novartis, the University of ...